• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.13%

    More On AZN.L

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    AstraZeneca PLC (AZN.L)

    -LSE
    4,357.00 Down 9.50(0.22%) Jun 2
    Add to Portfolio
    ProfileGet Profile for:
    AstraZeneca PLC
    2 Kingdom Street
    London, W2 6BD
    United Kingdom - Map
    Phone: 44 20 7604 8000
    Fax: 44 20 7604 8151
    Website: http://www.astrazeneca.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Major
    Full Time Employees:57,500

    Business Summary 

    AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on AstraZeneca PLC

    Key Executives 
     PayExercised
    Mr. Pascal Soriot , 56
    Chief Exec. Officer, Exec. Director and Member of Disclosure Committee
    N/AN/A
    Mr. Marc Dunoyer , 63
    Chief Financial Officer and Exec. Director
    N/AN/A
    Mr. David Smith , 50
    Exec. VP of Operations & Information Services
    N/AN/A
    Dr. Catherine Bonuccelli M.D.,
    VP of External Scientific Affairs
    N/AN/A
    Mr. Karl H ,
    Director of Investor Relations
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in GBp.